February 1st 2023
Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.
January 31st 2023
Study Highlights Need For Policies To Seek Utilization, Support Sustainable Market Of Biosimilars
Shifts towards on-patient and higher-cost therapies have been observed in TNF-alpha inhibitor biosimilar availability. Therefore, the importance of investing in biosimilars is encouraged.
Adverse Reactions, Disease Activity Cited as Disease-Dependent Factors for Biosimilar Refusal
Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.
Patients with Rheumatoid Arthritis Satisfied with Switch to Adalimumab Biosimilar
Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.